A busy Monday morning brief spans corporate defence, clinical catalysts, and a strategic pivot forced by a factory accident. The most eye-catching headline involves a reported attempt to take over easyJet (LSE:EZJ), with the airline said to have rebuffed three approaches, while Babcock posts record free cash flow against a heavy contract charge, and Ondine Biomedical prepares to deliver Phase 3 top-line data within weeks.
easyJet rebuffs three takeover approaches from Castlelake
easyJet has rejected three separate takeover bids from US investment firm Castlelake, according to reports covered in this morning's briefing. The firm is said to have structured its approach to satisfy European Union rules requiring EU-controlled ownership of airlines operating within the bloc, a regulatory constraint that has shaped the mechanics of the proposed deal. easyJet (LSE:EZJ)'s board has declined all three approaches.
Maintel fundraising clears all conditions ahead of admission
Maintel Holdings (AIM:MAI) has confirmed that all conditions to its £5.5 million fundraising have been satisfied following the completion of an accompanying refinancing. The company expects admission of the new shares to proceed on schedule, with the refinancing providing an updated financial footing alongside the fresh equity.
Ondine Biomedical's LANTERN Phase 3 readout due within three weeks
Ondine Biomedical (AIM:OBI) has confirmed that the database lock for its LANTERN Phase 3 trial is imminent, with statistical analysis to follow and top-line results expected within one to two weeks of that lock. The trial is evaluating the company's photodisinfection technology, and the readout represents the most significant near-term catalyst on Ondine's clinical timeline.
Babcock posts record free cash flow as Type 31 charge weighs on profit
Babcock International (LSE:BAB) delivered 8% organic revenue growth in the year to 31 March, with the defence and nuclear engineering group generating record free cash flow. However, a £140 million charge on its troubled Type 31 frigate programme suppressed reported operating profit, offsetting what was otherwise a strong operational performance across its core divisions.
Synthomer flags ahead-of-expectations Q2 on Iran conflict tailwinds
Synthomer (AIM:SYNT) issued a positive trading update, flagging that second-quarter momentum has run ahead of its own expectations. The specialty polymers supplier attributed part of the uplift to supply chain disruption triggered by the Iran conflict, which boosted volumes in its Health and Protection segment. The group expects year-on-year progress across the full year of 2026.
BATM Advanced Communications divests medical and distribution units for US$37 million
BATM Advanced Communications (AIM:BVC) has agreed to sell a portfolio of medical, pharmaceutical and distribution subsidiaries in a $37 million deal, exiting non-core operations to concentrate entirely on secure networking, quantum encryption and cybersecurity. The disposal marks a significant reshaping of the group's structure and sharpens its focus on higher-growth technology verticals.
NextEnergy Solar Fund grows income and strengthens balance sheet
NextEnergy Solar Fund (LSE:NESF) reported total income of £141.3 million for the year to 31 March, with its cash position strengthened as asset disposals and a revised dividend policy took effect. The specialist solar investor described the period as a strategic reset, with debt reduction and capital discipline running alongside the income growth.
Pantheon Infrastructure deploys $55 million into US renewable platform Terra-Gen
Pantheon Infrastructure has committed approximately $55 million to Terra-Gen, a US renewable energy platform operating 4 GW of solar, wind and battery storage assets with a 16 GW development pipeline. The investment, equivalent to roughly £41 million, represents a significant deployment of capital into the US clean energy buildout.
Avacta doses first patient in AVA6103 Phase 1 cancer trial
Avacta Group (AIM:AVCT) has enrolled its first patient in the FOCUS-01 Phase 1 trial of AVA6103, its second-generation cancer therapy. The milestone follows £41.5 million raised over the past 18 months, with the company's cash runway now extended to early 2027. AVA6103 is built on Avacta's Affimer platform and represents the group's lead clinical asset.
Clean Power Hydrogen pivots to IP licensing after electrolyser incident
Clean Power Hydrogen (AIM:CPH2) has abandoned its manufacturing ambitions following a hydrogen-oxygen ignition during final factory acceptance testing of its MFE220 electrolyser. The incident has prompted a fundamental strategic shift, with the company now pursuing an intellectual-property licensing model rather than direct production. The pivot represents a material change to the group's business plan and commercial strategy.
Kazera Global settles Aftan dispute for US$10.5 million over structured payment schedule
Kazera Global (AIM:KZG) has executed a definitive agreement with Hebei Xinjian Construction, replacing an arbitration award with a structured settlement of US$10.5 million. Payments are scheduled to run to December 2029, with ownership of the Aftan asset withheld until US$7.125 million has been received. The agreement draws a line under a protracted dispute and provides Kazera with a defined recovery path.
Coinsilium triples net assets after £17 million raise and Bitcoin treasury build
Coinsilium Group (AQSE:COIN) reported a tripling of net assets to £14.6 million across 2025, following a series of placings that raised £17 million in aggregate. The Aquis-quoted digital asset investor used the proceeds to fund a new Bitcoin treasury strategy, accumulating 182 Bitcoin over the period. The results mark a transformational year for the group's balance sheet.
Schroders Capital Global Innovation Trust upsizes tender offer to £23.5 million
Schroders Capital Global Innovation Trust (LSE:INOV) has increased the size of its tender offer to £23.5 million, citing portfolio cash generation as the enabling factor. The offer is scheduled to complete on 29 September, providing shareholders with an enlarged liquidity event as the trust continues its capital management programme.
ADM Energy appoints Vega Oil founder as US subsidiary COO ahead of deal close
ADM Energy (AIM:ADME) has named Chris Czuppon, founder of Vega Oil, as chief operating officer of its ADM Energy USA subsidiary. The appointment comes as the Vega Upstream acquisition remains on track to complete by the end of June, with Czuppon's operational background in the mid-continent region expected to support integration and early execution.
Anglo Asian Mining commissions Worley for copper feasibility studies
Anglo Asian Mining (AIM:AAZ) has appointed Worley Europe to complete feasibility studies at its Xarxar and Garadag copper deposits in Azerbaijan. Results from the two studies are expected between mid-2027 and the first half of 2028, marking a significant step in the company's effort to advance its copper portfolio toward development decisions.
Conroy Gold step-out drilling extends Eastern Zone toward Corcaskea
Conroy Gold and Natural Resources (AIM:CGNR) has reported new step-out drill results from its Clontibret project in Ireland, with nine gold-bearing lodes intersected approximately 150 metres north of previous holes. The results reinforce the interpreted structural link between the Eastern Zone and the Corcaskea target, extending the known footprint of mineralisation along the corridor.
Hamak Gold records best intercept yet at Akoko North in Ghana
Hamak Gold (AIM:HAMA) has reported its strongest drill result to date from the Akoko North prospect in Ghana, returning 44 metres at 1.61 grams per tonne gold from near surface. Drilling is now moving to a second target located 13 kilometres to the south, as the company continues to build out its resource base in West Africa.
GEO Exploration finds visible gold at Gorge Project in Western Australia
GEO Exploration (AIM:GEO) has completed its first field reconnaissance at the recently acquired Gorge Project, returning visible and coarse gold across two prospects. A copper-rich gossan was also identified at a third prospect, broadening the exploration target suite at the Western Australian project and supporting the case for follow-up work.
Wishbone Gold hits shallow gold at Red Setter with mineralisation open at depth
Wishbone Gold (AIM:WSBN) has released first assay results from reverse circulation drilling at its Red Setter project, with gold returned from as shallow as 45 metres. Notably, the deepest hole ended in mineralisation, indicating the system remains open at depth and supporting the case for further drilling to test extensions.
Forgent begins maiden drilling at Peak Hills Gold-Copper Project
Forgent (AIM:FORG) has commenced its maiden drill campaign at the Peak Hills gold-copper project in Western Australia. Initial results are expected in early August, marking the first direct test of the project's subsurface geology since the company's AIM listing.
Mila Resources launches first geophysical survey at Monal in Queensland
Mila Resources (AIM:MILA) has started an induced polarisation survey at its Monal gold-copper project in Queensland, targeting porphyry-style mineralisation signatures at the Child's prospect. The survey is designed to generate drill-ready targets, representing the first systematic geophysical work at the project.
Solvonis Therapeutics clears key pharmacokinetic hurdle for esketamine programme
Solvonis Therapeutics (AIM:SVNS) has reported that bridging data for SVN-002 demonstrate its sublingual-buccal delivery route can match the exposure profile of intranasal esketamine. The pharmacokinetic milestone clears a critical requirement on the pathway to a US Investigational New Drug submission for the company's alcohol use disorder programme.
Timor-Leste regulator moves to cancel Sunda Energy's Chuditch gas licence
Sunda Energy (AIM:SNDA) has received a notice of intention to terminate its Production Sharing Contract covering the Chuditch gas field in Timor-Leste, after the company failed to drill an appraisal well by the required contractual deadline. The notice represents a material threat to Sunda's primary asset and the company is expected to respond formally to the regulator.
CelLBxHealth halves revenue but cuts costs sharply and targets 50% growth in 2026
CelLBxHealth (AIM:CLBX) reported full-year revenue of £1.4 million, a 52% decline year on year, as the AIM-listed circulating tumour cell technology company restructured its operations. The group cut its operating cost base by more than £6.6 million and guided for at least 50% revenue growth in 2026, framing the year as a deliberate reset ahead of a return to expansion.
Ocado confirms CEO succession planning is actively under way
Ocado Group (LSE:OCDO) has confirmed that its board is engaged in long-term succession planning for the chief executive role, following media speculation over Tim Steiner's future at the company. The statement acknowledges the process is active, though no timeline or candidate detail was provided.
Rift Helium maps out 12-month drill path following AIM debut
Rift Helium (AIM:RIFT) has set out its near-term operational roadmap following its April AIM listing, confirming that £8.1 million in IPO proceeds are fully committed. A 3D seismic campaign is planned for later this year, with a first drilling campaign in Tanzania targeted for the first half of 2027.
Nordex secures 484 MW of new US wind turbine orders across three projects
Nordex has won three new US contracts totalling 484 MW, comprising 88 turbines across two of its current product lines. The orders add to the German manufacturer's US order book as demand for utility-scale wind capacity continues to build across the mid-continent and other regions.
Proteome Sciences wins clinical chemoproteomics contract ahead of new trial
Proteome Sciences (AIM:PRM) has secured a new clinical contract on its target engagement platform, with a further trial programme expected to follow later in 2026. The contract win demonstrates commercial traction for the company's chemoproteomics services ahead of what the group expects to be an active second half of the year.
Distil converts Ardgowan loan note and secures three-year rent credit
Distil (AIM:DIS) has completed the early conversion of its £3 million convertible loan note in Ardgowan Distillery, receiving £395,000 in cash and a rent waiver of up to £170,000 on its Blackwoods Brand Home, equivalent to approximately three years of payments. The transaction simplifies Distil's balance sheet exposure to Ardgowan while delivering near-term cash and cost relief.
Fusion Antibodies receives Canadian patent allowance for antibody library platform
Fusion Antibodies (AIM:FAB) has received confirmation from Canada's intellectual property office that the claims in its patent application, covering two antibody families and associated design methods, are patentable. The allowance extends the geographic reach of the company's intellectual property protection for its antibody library technology.
Genflow chairman to address RNA therapeutics panel at BIO International Convention
Genflow Biosciences (AIM:GENF) has confirmed that its non-executive chairman will participate in a panel discussion on RNA therapeutics at the BIO International Convention, one of the biotechnology industry's largest annual gatherings. The appearance provides the company with a platform to raise its profile among institutional and industry audiences at a key sector event.
ValiRx terminates University of Dundee drug discovery collaboration
ValiRx (AIM:VAL) has ended its evaluation agreement with the University of Dundee's Drug Discovery Unit after the candidate technology failed to meet the criteria required for the company to exercise its option to license it. The termination closes out the collaboration without a licensing transaction, removing the programme from ValiRx's pipeline.
Eco Buildings Group reaches second floor at Albania development
Eco Buildings Group (AIM:ECOB) has completed the second-floor structure of the first apartment block at its Rolling Hills development in Tirane, Albania. Construction of the third and final floor is now under way, marking continued physical progress at the company's inaugural international project.
